Hims & Hers Health on Monday announced a collaboration with Novo Nordisk as part of a new strategy for weight-loss care treatments involving GLP-1 drugs. The agreement settles a patent dispute between the health and wellness platform and the maker of Wegovy and Ozempic.
In the United States, Him & Hers now plans to provide GLP-1 customers access to a broad assortment of FDA-approved medications and offer compounded semaglutide through the platform on a limited scale. By aligning its domestic and international models in weight loss, it will become the largest global consumer health platform for access to more affordable, approved medications, according to a company news release.
Since Hims & Hers entered the market in 2023, a broader range of FDA-approved GLP-1 treatments have become available at more affordable prices. There also are more flexible dosing options and greater diversity of form factors, accelerating customer demand for branded, FDA-approved medications.
Novo Nordisk sued Hims & Hers for patent infringement last month when it began selling a compounded version of Wegovy for $99 a month. Hims & Hers removed the product after the U.S. Department of Health and Human Services referred the matter to the Justice Department over potential violations of federal drug law.
As a part of the agreement, the company no longer will advertise compounded GLP-1 offerings on its platform or in its marketing. Existing patients will have the opportunity to transition to FDA-approved medicines when determined clinically appropriate by their providers. For what is anticipated to be a limited set of customers whose clinical needs cannot be met using the increasingly varied set of commercially available FDA-approved GLP-1s, Hims & Hers plans to offer access to compounded GLP-1s if a provider determines it is clinically necessary.
Hims & Hers will bring Ozempic 0.5 mg, 1 mg and 2 mg injections and Wegovy pills and injections to the platform later in March. In coming months, the company will educate U.S. weight-loss customers about their options across an expanded assortment of FDA-approved treatments. When providers determine it to be clinically appropriate, it will support a seamless transition to these medications. In the future, Hims & Hers and Novo Nordisk hope to collaborate to bring other products to market as they become available, further increasing the range of innovative treatments on the platform from which providers can choose.
"We see tremendous growth opportunities in the U.S. with the expanding assortment of branded GLP-1 medications," said Andrew Dudum, co-founder and CEO of Hims & Hers. "I'm excited to have a great partner in Novo Nordisk as we work to create a new model that works for everyday people. This collaboration reflects what's possible globally when drugmakers, biotech companies and diagnostic leaders partner with consumer platforms to support scaled distribution of their latest medical innovations."
© Arc, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to TMSalesOperations@arc-network.com. For more information visit Asset & Logo Licensing.